Charles Schwab Investment Management Inc Prelude Therapeutics Inc Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 127,370 shares of PRLD stock, worth $485,279. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,370
Previous 124,700
2.14%
Holding current value
$485,279
Previous $532,000
13.35%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding PRLD
# of Institutions
59Shares Held
34.2MCall Options Held
200Put Options Held
0-
Orbimed Advisors LLC San Diego, CA10.9MShares$41.6 Million1.16% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$38.6 Million0.61% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.13MShares$15.7 Million0.4% of portfolio
-
Boxer Capital, LLC San Diego, CA2.57MShares$9.79 Million0.63% of portfolio
-
Black Rock Inc. New York, NY1.1MShares$4.18 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $139M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...